The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML.
R. M. Stone
Consultant or Advisory Role - Novartis
H. Dohner
No relevant relationships to disclose
G. Ehninger
Stock Ownership - Novartis
Honoraria - Novartis
M. Villeneuve
No relevant relationships to disclose
T. Teasdale
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. D. Virkus
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
L. R. Bressler
No relevant relationships to disclose
M. M. Seiler
No relevant relationships to disclose
G. Marcucci
No relevant relationships to disclose
R. A. Larson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis